Skip to Main Content

Paper Details

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Ann Oncol
44
2016
Author NameAffiliation
Michiel S van der Heijden
Alexandre R ZlottaUniversity Health Network, Princess Margaret Cancer Centre, University of Toronto
Bharati BapatSamuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto
Theodorus H van der KwastUniversity Health Network, Princess Margaret Cancer Centre, University of Toronto
  • 1 - 4

Datasets

Release 1.2